Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase.
Cellular immune mechanisms resulting in interferon-gamma (IFN-gamma) production are essential for protection against cutaneous leishmaniasis. Antigens of the intracellular amastigote form of the parasite, found in mammalian hosts, are likely to be good candidates for the induction of T cell response and protection from development of leishmaniasis. We purified a stage-specific antigen from amastigote soluble antigen (A-SLA) of Leishmania major by immunoaffinity chromatography. The purified protein was characterized as a cysteine proteinase with enzymatic activity which is inhibited by E-64, and it was named the amastigote cysteine proteinase (ACP). BALB/c mice were immunized by two intraperitoneal injections, at a month interval, of 5 microg of ACP or A-SLA in Freund's complete adjuvant (FCA). Animals were challenged 4 weeks later with 106 L. major promastigotes and examined 4 months after the last injection. The immunized animals developed significantly smaller or no lesions compared with controls. Spleen cells from immunized mice showed a significant proliferative response and produced a high level of IFN-gamma in response to ACP, suggesting the induction of Th1 cells after immunization. These results make 24-kD ACP a possible component for an eventual cocktail vaccine against L. major infection.
Rafati
S
S
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran. rafatisy@nrcgeb.ac.ir
Baba
A A
AA
Bakhshayesh
M
M
Vafa
M
M
D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology / Q000302:isolation & purification / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology; D002455:Cell Division / Q000276:immunology; D003546:Cysteine Endopeptidases / Q000276:immunology* / Q000302:isolation & purification / Q000627:therapeutic use*; D005260:Female; D007111:Immunity, Cellular; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D018320:Leishmania major / Q000201:enzymology* / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000276:immunology / Q000517:prevention & control*; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D016052:Protozoan Vaccines / Q000276:immunology / Q000302:isolation & purification / Q000627:therapeutic use*; D012995:Solubility; D013601:T-Lymphocytes / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology / Q000627:therapeutic use
D000953:Antigens, Protozoan; D016052:Protozoan Vaccines; D015164:Vaccines, Inactivated; D007371:Interferon-gamma; D003546:Cysteine Endopeptidases